REGN5093

· Regeneron Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for REGN5093, covering 2026-03-18 to 2026-03-18. Get the full timeline:

Most recent: Clinical Trial Update: A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer [Phase 1, Phase 2]

See pricing